Knockdown of HSDL2 inhibits lung adenocarcinoma progression via down-regulating AKT2 expression

Yujia Shi1,2, Zhengdao Mao2, Yanhua Huang2

  • 1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China.

Bioscience Reports
|March 27, 2020
PubMed

Insights

Hydroxysteroid dehydrogenase-like 2 (HSDL2) promotes lung adenocarcinoma growth and metastasis by upregulating AKT2. Knocking down HSDL2 inhibits cancer progression and improves patient survival, revealing HSDL2 as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Expression Analysis

Background:

  • Lung adenocarcinoma is a major cause of cancer mortality.
  • The molecular mechanisms driving lung adenocarcinoma progression require further elucidation.
  • The role of hydroxysteroid dehydrogenase-like 2 (HSDL2) in lung cancer is not well understood.

Purpose of the Study:

  • To investigate the role of HSDL2 in lung adenocarcinoma.
  • To identify the molecular mechanisms by which HSDL2 influences lung cancer progression.
  • To assess the therapeutic potential of targeting HSDL2.

Main Methods:

  • Gene knockdown using small interfering RNA (siHSDL2) to reduce HSDL2 expression.
  • In vitro assays (proliferation, cell cycle, apoptosis, clone-formation, invasion, migration) and in vivo studies (growth, metastasis).
  • Microarray hybridization and gene expression analysis to profile mRNA changes; Western blotting for protein analysis; rescue experiments with AKT2 overexpression.

Main Results:

  • HSDL2 was significantly upregulated in lung adenocarcinoma tissues, correlating with worse patient survival.
  • HSDL2 knockdown inhibited lung adenocarcinoma cell proliferation, migration, invasion, and metastasis both in vitro and in vivo.
  • HSDL2 knockdown altered gene expression, notably downregulating AKT2 and BIRC3, and upregulating ERK phosphorylation; AKT2 overexpression rescued the inhibitory effects of HSDL2 knockdown.

Conclusions:

  • HSDL2 acts as an oncogene promoting lung adenocarcinoma growth and metastasis.
  • HSDL2 facilitates lung cancer progression primarily through the AKT2 signaling pathway.
  • HSDL2 represents a promising therapeutic target for lung adenocarcinoma treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
9.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K